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1. Introduction 
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD). The 
pathogenesis of IBD is complex and so far not fully understood. The long-term clinical 
outcome of UC is hard to predict. Some clinical phenotypes of UC may to some extent 
predict the severity of the disease, but the clinical impact of these predictors is minor. . The 
new immunomolecular understanding of the pathophysiological mechanisms behind the 
disease, and especially the genetic engineering knock out animal models in early 1990’s, was 
the start of a new therapeutic strategy: the targeting therapy. Based on new knowledge of 
proinflammatory and anti-inflammatory molecules, new therapeutic targets were 
established to attack specific components of the inflammatory cascade. TNF-alpha was the 
first molecule to be blocked with effects on the disease activity first described in the 
animal models and then described in humans in 1995 for Crohns disease (CD). Later on, 
numerous other targeting molecules have been developed with more or less efficacy. So 
far the anti-TNF agent infliximab (IFX) is the only targeting agent that has been found to 
be effective in UC. However, a lot still needs to be done in order to achieve “personalized 
engineered therapy” in IBD. After some ten years experiences with targeting therapy the 
major unresolved questions are: which UC patients will have the greatest effect of 
targeting therapy inducing a “deep, longstanding“ remission and prevent severe outcome 
such as colectomy? Which patients are in the need of long-term maintenance therapy? If 
and when can target therapy be stopped? Few studies have investigated potential 
predictors of the disease’s severity and future clinical outcome after the introduction of 
targeting therapy. Therefore, after ten years with targeting therapy of UC, what clinical, 
biological or histological markers could give some answers to these questions addressed 
above?  
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2. Clinical markers in various clinical settings 
Definition of a biological marker 
Biomarker is defined by National Institute of health (NIH) as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacological responses to a therapeutic intervention” (Colburn, 
2000). An optimal biomarker has to fit into several criteria to be of clinical value. It has to 
be accurate, reproducibly, acceptable for the patient, and have high sensitivity and 
specificity for the outcome it is expected to identify (Mendoza and Abreu, 2009). A 
prognostic biomarker should indicate future severe clinical outcomes such as intestinal 
stenosis and need of surgical resections. This would give valuable information such as 
priority of treatment options and closer follow-up visits. A predictive biomarker should 
give information of therapeutic effect of agents such as targeting therapy. The ideal 
biomarker assay from tissue or body fluids should be accurate, reproducible with high 
sensitivity and specificity. The biomarker concept is old. Despite this, there is a lack of 
validation of new candidate biomarkers in order to give a useful guidance to the clinicians 
(2010).  
So far no ideal biomarkers have been found in IBD, but several serological and fecal 
biomarker candidates have been proposed (Mendoza and Abreu, 2009). A biomarker in IBD 
should predict: the clinical outcome with special emphasis of patients with complicated 
disease; which therapeutically strategy should be used and especially which patients would 
be suitable for the high cost treatment of targeting agents; and finally are there biomarkers 
of resistance to therapy. 
In this review we present the candidate biomarkers based on “old”, established methods 
easily performed in a clinical setting, and biomarkers from the new era of high technological 
methods. 
2.1 Demographic factors (clinical phenotypes) as predictors of disease severity and 
response of treatment 
2.1.1 Smoking, age and early onset of disease 
In a retrospective study of Roth et al (Roth et al., 2010) one hundred and two UC patients 
were investigated. In this study charts were reviewed using standardized data collection 
forms. Disease severity was generated during the chart review process, and non-endoscopic 
Mayo Score criteria were collected into a composite. They found that UC severity was 
associated with younger age at diagnosis and year of diagnosis. Previous studies have 
shown that patients with early onset UC are more prone to colorectal cancer (Eaden et al., 
2001). In the study of Roth et al (Roth et al., 2010) disease severity at presentation did not 
correlate with the severity index over the disease course, nor did delay from diagnosis to 
treatment. This is in contrast to the literature presented in a review article by Sandborn 
(Sandborn, 1999) who found that classifying presentations into one of four severity 
categories was useful for prognosticating disease. Another intriguing result of the study by 
Roth et al was that smoking status did not predict disease severity (Roth et al., 2010). 
Multiple previous studies have found that smoking is a protective factor (Calkins, 1989), 
while non- or ex-smokers have a higher risk of relapsing disease (Hoie et al., 2007). The 
limitations of the study by Roth et al are that it is retrospective in design and relies heavily 
on chart review.  
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2.1.2 ANCAs and ASCA 
Perinuclear anti-neutrophil antibody (ANCAs) is associated with chronic inflammatory 
diseases as Wegener`s granulomatosis, rheumatoid arthritis and UC (Mendoza and Abreu, 
2009). In CD the seroprevalence of ANCA ranges from 2-28% and in UC 20-85% (Mendoza 
and Abreu, 2009). The sensitivity and specificity in diagnosing IBD range from 50-70% and 
80-85%, respectively (Mendoza and Abreu, 2009). Anti-saccharomyces cerevisiae antibodies 
(ASCA) are found in 39%-69% of CD patients, but only in 5-15% of UC patients (Mendoza 
and Abreu, 2009). The sensitivity and specificity in diagnosing IBD range from 65-70% and 
80-85%, respectively (Mendoza and Abreu, 2009).  
The clinical value of ANCA or ASCA to differentiate IBD from IBS patients is limited 
because of low sensitivity. Serologic evaluation of ANCAs and ASCAs may be helpful in 
patients with indeterminate colitis (Joossens et al., 2002). Interestingly, pANCA in CD 
patients have been negatively associated with small small bowel disease, fibrostenosis and 
small bowel surgery (Vermeire et al., 2004), while ASCAs have been associated with several 
CD clinical phenotypes (Vermeire et al., 2001;Walker et al., 2004). Further, ASCAS have been 
associated with small bowel disease in CD in addition to stricturing as well as penetrating 
disease behavior (Mow et al., 2004; Vermeire et al., 2001; Walker et al., 2004). There is also 
found a strong association between development of pouchitis and high level of ANCAs 
(Fleshner et al., 2001; Vernier et al., 2004). Though, this has not been confirmed in another 
study (Aisenberg et al., 2004).     
2.2 Biochemical factors reflecting disease activity or responses to specific therapies 
(C-reactive protein, calprotectin) 
2.2.1 C-reactive protein 
2.2.1.1 CRP production in ulcerative colitis and Crohn´s disease  
C-reactive protein (CRP) is an acute phase protein that increases during inflammation and 
has a short half life (19 hours) and will therefore rapidly decrease after resolution of the 
inflammation (Vermeire et al., 2006). Serum CRP as a biomarker in the course of UC has 
been studied by number of workers but its usefulness as a diagnostic screening test has not 
been fully assessed. However, CRP is the most sensitive screening biomarker compared to 
other biomarkers in adult population for detecting IBD, where CD has the strongest CRP 
response of the two diseases (Lewis, 2011; Vermeire et al., 2006). The reason for this 
difference between the two diseases is not known. Both CD patients and UC patients have 
increased levels of cytokines belonging to T-helper-1 response (Olsen et al., 2007; Vermeire et 
al., 2006). Santos et al investigated 957 subjects and found strong association between CRP 
and central abdominal obesity (Santos et al., 2005).  Positive association between BMI and 
CRP has also been observed in otherwise healthy adults and children, suggesting a state of 
low-grade systemic inflammation in obese persons (Visser et al., 1999; Visser et al., 2001).  
Several groups have investigated adipose tissue and concluded that invasion of 
inflammatory cells in adipose tissue leads to increased levels of various pro-inflammatory 
cytokines including IL-6, IL-8, TNF-alpha, IL-10 and IL-18, potentially linking fat and 
inflammation (Fantuzzi, 2005;Isakson et al., 2009). It has been speculated whether the 
transmural inflammation in CD and possible involvement of mesenteric fat which is a major 
site of IL-6 and TNF-alpha synthesis may explain the difference of the two diseases. 
Colombel et al examined whether small bowel inflammation at CT enterography correlated 
with endoscopic severity and CRP in 143 patients with CD (Colombel et al., 2006). They 
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concluded that CRP correlated with radiological findings of perienteric inflammation 
(increased fat density), but not of inflammation limited to the small bowel wall, 
underscoring the potential role of perienteric inflammation in CRP response in CD. Solem et 
al confirmed this finding in a recent study where abnormal small bowel radiographic 
imaging was not associated with CRP elevation in CD patients (Solem et al., 2005). The final 
conclusions concerning the difference of CRP in UC and CD patients are still not drawn. 
However, even though the CRP response is strongest in CD, the overlap between CD and 
UC patients in CRP levels make it difficult to use it for differential diagnosis between the 
two diseases.  
2.2.2 CRP, genetic factors and IBD 
Individual genetic factors may also contribute to differences of CRP levels. Recent studies 
have suggested that polymorphisms in the CRP gene account for the inter-individual 
differences in baseline CRP production in humans (Carlson et al., 2005) but so far results are 
conflicting (Vermeire et al., 2006). Interestingly, Greenfield et al investigated 194 healthy 
female twins to examine the relationship between CRP, BMI, blood pressure, lipids and 
apolipoproteins, independent of genetic influences (Greenfield et al., 2004). They concluded 
that CRP was strongly related to total and central abdominal obesity, blood pressure and 
lipid levels independent of genetic influences (Greenfield et al., 2004).   
2.2.3 CRP and the role in predicting disease activity in IBD  
In a study by Prantera et al (Prantera et al., 1988) 60 UC patients were investigated and they 
found that the disease severity and the presence of signs and symptoms of toxicity seemed 
likely to be determined by the amount of colonic tissue involved by inflammation, both in 
depth and in extent. CRP appeared the most reliable factor reflecting activity and extension 
of lesion. In a study from Mayo Clinic (Solem et al., 2005), 43 UC patients were investigated. 
In this study they concluded that serum CRP levels were associated with increase in 
biomarkers of inflammation (except platelets) and an active disease at ileocolonoscopy. 
However, histological activity was not associated with CRP concentrations in UC patients. 
These results should though be interpreted with caution given the relatively small sample 
size of 43. In another study Chouhan et al. (Chouhan et al., 2006) concluded that 
measurement of CRP levels is a simple method of assessing disease activity and extent in 
UC. They concluded that CRP level >12 mg/L is indicative of severe and extensive disease 
and that a change in CRP following therapy is a good parameter to assess the effect of the 
drug on the underlying inflammation. A decrease in CRP in response to therapy is objective 
evidence that the drug has a beneficial effect on gut inflammation even in patients with little 
change in symptoms. On the other hand, persistently raised CRP indicates failure of the 
therapy to control mucosal inflammation (Pepys and Hirschfield, 2003).  
In an interesting newly published prospective study of Henriksen et al (Henriksen et al., 
2008) CRP was measured at diagnosis and after 1 and 5 years in patients diagnosed with 
IBD in southeastern Norway. After 5 years, 454 patients with UC and 200 with CD provided 
sufficient data for analysis. The authors concluded in line with earlier findings that patients 
with CD had a stronger CRP response than those with UC. In patients with UC, CRP levels 
at diagnosis increased with increasing extent of disease. However, in this study 71% of 
patients with UC still had CRP levels within the normal range and mean CRP values were 
within the normal range in all UC subgroups at 5 years. Further they found that in patients 
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with UC with extensive colitis, CRP levels above 23 mg/l at diagnosis predicted an 
increased risk of surgery (odds ratio (OR) 4.8, p=0.02). In patients with ulcerative colitis, 
CRP levels above 10 mg/l after 1 year predicted an increased risk of surgery during the 
subsequent 4 years (OR 3.0, p=0.02). Interestingly, five years later the authors found no 
difference in CRP levels between 195 patients who underwent colonoscopy and were in 
endoscopic remission and those with endoscopic inflammation (mean 6 mg/l versus 7 mg/l, 
p=0.59). This finding is somehow in contrast to the results of increasing extent of UC 
correlates with increasing CRP levels. The authors conclude that the results may indicate 
that CRP is of limited value in predicting disease activity during follow-up. The strength of 
this Norwegian study is that it is prospective in design (Henriksen et al., 2008). In addition 
the size of the Norwegian study population seems to be appropriate, in contrast to the study 
from Mayo Clinic. A minor limitation of the Norwegian study is that it is a multicenter 
study with different clinicians and therefore there may be some grade of inter-observer 
variations. 
2.2.4 CRP and the role in predicting response to therapy 
Several clinical studies have investigated the role of CRP for monitoring the effect of 
treatment. A decrease in CRP in response to therapy could be objective evidence that the 
drug has a beneficial effect on gut inflammation. In a recent published Cochrane analysis, 
the authors included all the randomized controlled trials comparing natalizumab to a 
placebo or control therapy for the induction of remission in CD (Macdonald and McDonald, 
2007). Subgroup analyses demonstrated statistically significant differences in clinical 
response at twelve weeks favoring three infusions of natalizumab (4 mg/kg) over placebo 
for CD patients with an elevated CRP at baseline (Macdonald and McDonald, 2007). In a 
Belgian study 153 CD patients were included and treated with infliximab. Baseline CRP>5 
mg/l before the start of therapy was associated with a higher response (76%) compared with 
patients with CRP<5 mg/l (46%). In line with the findings above, Schreiber et al 
investigated the efficacy of certolizumab in 292 CD patients and concluded that in the 
subgroup of patients with low CRP the placebo response rates were high (Schreiber et al., 
2005). The situation in UC is more unclear since most of the studies performed concerning 
CRP and prediction of response to anti-TNF-alpha treatment are done on CD patients 
(Mendoza and Abreu, 2009; Vermeire et al., 2006). However, Ferrante et al investigated 
predictors of early response to infliximab in 100 patients with UC (Ferrante et al., 2007). They 
concluded that pANCA+/ASCA- serotype and an older age at first infliximab infusion were 
associated with a suboptimal early clinical response, while CRP ≥5 was not a significant 
predictor (Ferrante et al., 2007). Other studies are done concerning which patients are most 
likely to respond to intravenous corticosteroid therapy for UC. Travis et al demonstrated 
that after three days intensive treatment with intravenous steroids, patients with frequent 
stools (> 8/day), or raised CRP (> 45 mg/l) needed to be identified, as most would require 
colectomy (Travis et al., 1996). However, clinical scores which is based on symptoms are in 
some studies found to more accurately identify UC patients who do not respond to 
intravenous corticosteroids than CRP (Turner et al., 2010).    
2.2.5 Summary 
Taken together, most of the clinical studies conclude that the values of CRP as a marker in 
detecting IBD range between 50-60% for UC and between 70-100% for CD and of course 
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depend on the cut off value used (Lewis, 2011;Vermeire et al., 2006). Several study results 
point in the direction that CRP levels increase with increasing clinical activity of UC. Still it 
is important to keep in mind that many of the IBD patients have CRP levels within the 
normal range at diagnosis and this means that measuring CRP does not necessarily 
differentiate between IBD and functional order (Henriksen et al., 2008;Lewis, 2011). In one 
Norwegian study CRP levels above 10 mg/l was a predictor of surgery in a subgroup of 
patients with UC, however few patients with UC underwent surgery in the study and the 
data should therefore be interpreted with caution. There are also conflicting results in the 
different studies concerning the correlation between CRP and endoscopic inflammation in 
UC and CRP and histological inflammation in UC. Further, in CD, a decrease in CRP levels 
in response to therapy is objective evidence that the drug has a beneficial effect on gut 
inflammation (Vermeire et al., 2006). In UC the correlation between CRP levels and benefit of 
treatment is less clear. In conclusion, further studies should be carried out to evaluate 
whether highly sensitive CRP assays are more sensitive markers of gut inflammation and 
disease outcome in IBD patients. The conflicting study results concerning endoscopic 
inflammation and histological inflammation and CRP underscore the fact that measuring 
CRP in serum is an indirect marker of an inflammation mainly located in the gut and 
therefore not an optimal biomarker.  
2.3 Calprotectin 
2.3.1 Introduction 
Calprotectin is a protein that removes 60% of the calprotectin protein from the cytosol 
(Lundberg et al., 2005). Since the first assay was introduced on the market, there has been a 
change related to the introduction of a new extraction buffer that gives a fivefold better yield 
of calprotectin during the extraction procedure (Ton et al., 2000). The concentration of 
calprotectin in feces is an indirect measure of neutrophils infiltrate in the bowel mucosa 
(Lewis, 2011). Fecal calprotectin levels fluctuate during the course of IBD, but it is well 
documented that it is persistently elevated during the disease relapse in both adults and 
children (Berni et al, 2004, Tibble et al, 2000 and 2001). However, calprotectin is not a specific 
marker. Increased levels are found in other diseases than inflammatory bowel disease, as in 
colorectal neoplasia, microscopic colitis, food allergy, active celiac disease, allergic colitis, 
cystic fibrosis, infection and polyps (Carroccio et al., 2003; Tibble et al., 2000a; van Rheenen et 
al., 2010). It is also found to increase after use of non-steroidal anti-inflammatory drugs, 
proton pump inhibitor and with increasing age (Carroccio et al., 2003; Tibble et al., 1999; van 
Rheenen et al., 2010).     
2.3.2 Calprotectin as a tool to differentiate IBD from IBS patients 
Several studies have been performed investigating the sensitivity and specificity of 
calprotecting in various clinical settings. In a meta-analysis study by von Roon et al, data 
from 30 studies was summarized, including 1210 IBD patients, to address whether fecal 
calprotectin could be used to differentiate IBS patients from IBD patients (von Roon et al., 
2007). The calculated sensitivity and specificity values were 0.95 and 0.91 respectively. The 
diagnostic precision of calprotectin for IBD was higher in children than adults. The fecal 
calprotectin threshold used in these studies was 50 microgram/gram (von Roon et al., 2007). 
In another summary by Gisbert et al, 14 different studies were compared (Gisbert et al., 
2009). They summarized that the calprotectin sensitivity range from 63-100% and the 
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specificity from 74-98% for the diagnosis of IBD , calculating mean sensitivity and specificity 
of 80% (95% CI, 77-82%) and 76% (95% CI, 72-79) (Gisbert et al., 2009). In a recent meta-
analysis by van Rheenen et al 13 studies were included, six in adults and seven in children 
and teenagers (van Rheenen et al., 2010). In the studies of adults, the pooled sensitivity and 
pooled specificity of calprotectin was 0.93 (95% confidence interval 0.85 to0.97) and 0.96 
(0.79 to 0.99) and in the studies of children and teenagers was 0.92 (0.84to 0.96) and 0.76 (0.62 
to 0.86). The lower specificity in the studies of children and teenagers was significantly 
different from that in the studies of adults (p=0.048). All three meta-analysis studies 
concluded that fecal calprotectin has a good diagnostic precision for separating organic and 
functional intestinal diseases and is a useful screening tool for identifying patients who need 
endoscopy for suspected IBD. However, the specificity of calprotectin was significant lower 
in children and teenagers compared to adults in the meta-analysis by van Rheenen, while in 
the study by von Roon the opposite result was found.    
There is a notably variation in the range in both pooled sensitivity and specificity in the 
different studies summarized in meta-analysis studies, worthwhile to discuss. There may be 
several explanations for these variations. When comparing different studies one must 
ensure that the patient populations for each of the two disease states are equivalent and that 
the study designs are comparable. In the study by Costa et al for example 71% of CD 
patients had small intestinal disease alone, with only 31% having colitis (Costa et al., 2005). 
These values are compared with 47% and 53%, respectively, in another study included in 
the summary (Tibble et al., 2000a). Thus there may be a possible selection bias influencing 
the final predicative values. Further, the disease activity in most of the studies was assessed 
by the Crohn’s disease activity index (CDAI), a test that is highly subjective and correlates 
poorly with inflammatory activity assessed by In111 labelled white cells and endoscopic 
indices (Saverymuttu, 1986). Finally the calprotectin assay has been changed (Ton et al., 
2000) in the period of the performed studies summarized by Gisbert et al (Gisbert et al., 
2009). In this summary 10/14 studies have used the new and more sensitive calprotectin 
assay and that may have influenced the final results, as commented by the authors (Gisbert 
et al., 2009). In the meta-analysis by van Rheenen et al the study quality was assessed using 
the QUADAS (quality assessment of studies of diagnostic accuracy included in systematic 
reviews) checklist and from this checklist they chose seven best differentiating items (van 
Rheenen et al., 2010). The other meta-analysis studies did not select studies in the same way 
and this may of course influence the difference in the pooled sensitivity and specificity 
values (Gisbert et al., 2009; von Roon et al., 2007). In addition, von Roon et al pooled the 
sensitivity and specificity separately contrary to general recommendations and included 
studies that featured a control group with healthy people, which leads to overestimation of 
diagnostic accuracy (van Rheenen et al., 2010; von Roon et al., 2007). The pooled sensitivity 
and specificity in meta-analysis should be interpreted with caution because of the 
heterogeneity in the different studies included. In summary, the final range of the sensitivity 
and specificity of calprotectin is still not settled, but the main conclusion that calprotectin 
has a good diagnostic precision, especially in adults is well documented.         
2.3.3 Calprotectin and differentiating between UC and CD 
The test seems not useful for differentiating between the two diseases (Canani et al., 2006; 
Silberer et al., 2005; Tibble et al., 2002; von Roon et al., 2007). When comparing the sensitivity 
and specificity of calprotectin with other serological tests as CRP, ESR, ANCA or ASCA, 
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calprotectin turn out as the best test in level with clinical scores (Gisbert et al., 2009;Tibble et 
al., 2002). Tibble et al included 602 patients where 263 had organic intestinal disease and 339 
had nonorganic disease (Tibble et al., 2002). Interestingly they found that both fecal 
calprotectin level and the Rome I criteria were significantly better screening discriminates of 
patients with organic or nonorganic intestinal disease (Odds ratio (OR), 27.8, positive 
predicative value (PPV), 0.76, negative predicative value (NPV), 0.89 and 13.3, 0.86, 0.69) 
than some other commonly used laboratory parameters, such as CRP (OR, 4.2, PPV, 0.67, 
NPV, 0.68) and ESR (OR, 3.2, PPV, 0.62, NPV, 0.69) (Tibble et al., 2002). Other studies have 
listed comparable values (Canani et al., 2006; Fagerberg et al., 2005; Tibble et al., 2000a). 
Sensitivity of calprotectin ranged from 92-95% and specificity ranged from 93-98%, while 
sensitivity of CRP ranged from 36-41% and specificity from 77-100%. For ESR the values 
ranged from 41-59% and specificity from 77-100%. For ASCA/PANCA, the sensitivity was 
77% and specificity was 88% (Canani et al., 2006).  
2.3.4 Calprotectin and relapse in IBD 
Tibbel et al have addressed whether calprotectin predict relapse in IBD (Tibble et al., 2000b). 
They observed that at 50 microgram/gram, the sensitivity and specificity of calprotectin for 
predicting relapse in all patients with IBD were 90% and 83%, respectively. In their study 
calprotectin levels of 50 microgram/gram or more predicted a 13-fold increased risk for 
relapse. They did not find CRP or ESR to be useful in predicting relapse of IBD (Tibble et al., 
2000b). Other studies have confirmed the results of Tibbel et al (Costa et al., 2005; D'Inca et 
al., 2008). 
2.3.5 Calprotectin and correlation with disease activity in IBD 
Several studies have investigated and found a correlation between calprotectin and the 
severity of IBD evaluated with clinical, endoscopic and histologic parameters (Berni et al., 
2004; Langhorst et al., 2005; Tibble et al., 2000a; Tibble and Bjarnason, 2001). However, 
calprotectin seems to be better correlated with disease activity in UC than in CD (Costa et al., 
2003; D'Inca et al., 2007). Though, it is important to have in mind that CDAI score is mostly 
based on clinical information and not sensitive concerning subclinical inflammation.    
2.3.6 Calprotectin as a marker of treatment response in IBD 
It is plausible that calprotectin decreases if a treated IBD patient achieves remission, but so 
far few studies have confirmed this hypothesis. In a small recent study 38 IBD patients were 
included and calprotectin was measured before and after treatment with topical/or systemic 
5-ASA or prednisolon or immunosuppressiva (Wagner et al., 2008). Using calprotectin 
values below 95th percentile of the normal range as a negative predictor of active disease 
after 8 week of treatment, they revealed a negative predicative value of 100%. However, 
using an elevated level of calprotectin as a positive predictor to detect ongoing active 
disease or treatment failure after 8 week of treatment, they calculated a positive predicative 
value of 38% in UC and only of 14% in CD (Wagner et al., 2008). Comparable results were 
demonstrated in another study, including 57 children with IBD treated with prednisolon 
(Kolho et al., 2006). In their series, the positive predicative value of fecal calprotectin for 
active IBD judged by colonoscopy was 0.7. They observed that calprotectin levels declined 
in line with the clinical improvement but seldom fell within the normal range. The authors 
suggested that this may be caused of an ongoing inflammation in a clinically silent disease 
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(Kolho et al., 2006).  An interesting study by Røseth et al included 45 IBD patients with 
normal calprotectin levels after treatment and demonstrated that in 44 of the 45 patients the 
appearance of both the colon and the terminal ileum was completely normal endoscopically 
(Roseth et al., 2004). Sensitive markers of mucosal healing in IBD are urgently needed and 
this small study indicates that calprotectin could be such a marker in IBD patients. Future 
properly powered studies are needed to evaluate calprotectin as a possible marker of 
successful treatment in IBD.  
2.3.7 Summary 
As concluded in the systematic review by von Rheenen et al, high concentration of 
calprotectin in feces is a strong argument to carry out a colonoscopy in order to rule out the 
presence of inflammatory bowel disease or other organic pathologies. Parallelism between 
fecal calprotectin levels and inflammatory bowel disease activity has been confirmed, 
although this fecal marker appears to better reflect the disease activity in UC than in CD. 
Further, increased calprotectin levels are found to predict increased risk for relapse in IBD. 
However, the test seems not useful for differentiating between the two diseases. Finally, 
calprotectin have a good diagnostic precision for separating IBD from non-IBD diagnosis 
overall, better than classically ESR, CRP, ANCA or ASCA.  
3. Histological parameters as predictors of disease severity or treatment 
response in IBD 
To our knowledge there are not many studies done addressing histological parameters as 
predictors of disease severity or treatment outcome in IBD. After several search in 
pubmed.com we managed to find only one study published in 1993 (Schumacher, 1993). 
Schumacher investigated the possibilities of differentiating between inflammatory bowel 
disease (IBD) and infectious colitis on clinical, microbiological, laboratory and histological 
grounds, a prospective study of 105 patients with a first attack of colitis was undertaken 
(Schumacher, 1993). The strongest histological predictor of IBD in this study was basal 
plasmocytosis, followed by more than two vertical crypt branches/MPF, crypt distortion, 
villous mucosa, mucosal atrophy, epithelioid granulomas and Paneth cell metaplasia. These 
signs were rarely or never found among patients with infectious colitis. Their frequency 
increased with the interval between the initial symptoms and the first biopsy. Lately, 
researchers have been focusing on other biomarkers in serum, faeces or mucosa in IBD 
patients searching for possible predictors of both disease activity and treatment response 
and compared these biomarkers with both histology and endoscopy in IBD patients.  
4. Mucosal inflammatory processes: The main source of biomarkers in IBD 
4.1 Introduction 
The biological tissue factors playing a role in the pro-inflammatory and anti-inflammatory 
process in IBD have been revealed by the omics technology and described in several 
overviews (Kaser et al., 2010;Neuman, 2007;Torres and Rios, 2008): microarray and 
quantitative real-time polymerase chain reaction (RT-PCR) analyses describe the gene 
expression of IBD-related proteins, the proteomics describe the translation of proteins 
including small oligopeptides, whereas the metabolomics describe all the metabolic 
endproducts of gene expressions. This gives a unique option for molecular fingerprinting. In 
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general, these tissue factors are linked to various immunological pathways belonging to the 
innate, adaptive and regulatory immune response including molecules such as cytokines, 
chemokines, adhesion molecules and other markers of activation with corresponding 
cellular and soluble receptors; immune cells and non-immune cells. Finally, a relatively new 
field in IBD, the metabolic fingerprints obtained from metabolomics studies (for review, see 
(Roda et al., 2010; Scaldaferri et al., 2010). So far there are few reports describing prognostic 
and predictive bioamarkers. In the following we will describe the candidate biomarkers 
predicting either clinical outcomes and/or response to therapy. Moreover, as there are very 
few documented biomarkers we will also add some molecules central in the inflammatory 
process in IBD that is of great interest in the future biomarker fingerprinting based on the 
new approaches in high technological omics.   
4.2 Proinflammatory cytokines 
4.2.1 TNF-α 
TNF-α is a cytokine well established inflammatory mediator of CD whereas contradictory 
reports exist in UC (Kaser et al., 2010; Neuman, 2007;Torres and Rios, 2008).  Some reports 
have found positive correlations with the degree of disease activity in UC (Akazawa et al., 
2002;Olsen et al., 2007) and CD (Olsen et al., 2007) but not in all for CD (Akazawa et al., 2002) 
and UC (Dionne et al., 1997).  
As far as we know no studies do exist on mucosal expressions of TNF-α and the prediction 
of the clinical course, whereas there are only few reports on the predictive value of mucosal 
TNF-α concentrations and the response to therapy. Pretreatment mucosal TNF-α 
concentrations were negatively correlated to response to Infliximab in CD (Schmidt et al., 
2007) and in UC (Olsen et al., 2007). These findings disagree with another report where low 
expression of TNF-α predicted a poor response to therapy in CD (Arsenescu et al., 2008). 
Increased levels of TNF-α were also observed in corticosteroid non-responders compared with 
responders to corticosteroid treatment in UC (Ishiguro, 1999), but not confirmed in another 
study (Raddatz et al., 2005). Finally, in a preliminary report, normalization of mucosal TNF-α 
seemed to predict a longstanding remission after stop of anti-TNF therapy both in UC (Olsen T 
et al., 2011a).  Finally, based on microarray technology in UC patients treated with nfliximab 
expression of TNF-receptor (SF11B), the receptor for the proinflammatory cytokine 13 (IL-13-
R) and the anti-inflammatory cytokine IL-11 predicted the clinical response 
4.2.2 IFN-γ, IL-1, IL-12  
TNF-ǂ exerts its proinflammatory effect through cytokines such as INF-γ, IL-1β and IL-6 
(Neuman, 2007). INF-γ is a mediator of inflammation in CD (Strober et al., 2010), whereas 
contradictory reports exist for UC (Kobayashi et al., 2008; Olsen et al., 2007). Finally, in one 
report increased levels of INF-γ  in intestinal T lymphocyte cultures were observed in relapsing 
perianal fistulising disease in CD after treatment with infliximab (Agnholt et al., 2003).  
IL-1ǃ was increased in CD and UC in one report (Dionne et al., 1998), and IL-1-receptor/IL-
1ǃ ratio is negatively associated to the IBD activity (Dionne et al., 1998). IL-12 is a 
proinflammatory cytokine known for gating (in synergy with IL-18) in a Th1 
direction/stimulating the IFN-γ synthesis in naïve T cells and is up-regulated in IBD 
(Neuman, 2007). IL-12 in addition to INF-γ and IL-6 is more increased in inflamed than in 
not inflamed mucosa (Leon et al., 2009). However, neither of these cytokines has been 
studied as potential biomarkers 
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4.2.3 IL-6 
IL-6 is a pleiotropic cytokine with regulatory effects on the inflammation. The cytokine plays 
an important role in the initial activation of immune response and in combination with the 
transforming growth factor (TGF-β), plays a pivotal role in TH17 polarization. Increased 
levels of the cytokine and its soluble receptor are increased in active CD and in UC (for 
review, see (Atreya and Neurath, 2005)), but their roles as biomarker are so unknown.  
4.2.4 IL-17/Il-23 
The first reports of increased density of IL-17 cells in the inflamed mucosa of IBD came in 
2003 (Fujino et al., 2003) and was confirmed by later studies (Kobayashi et al., 2008; Olsen T 
et al., 2011b). Both IL-17 and IL-23 are correlated to the severity of UC (Olsen T et al., 2011b) 
and are positive correlated to the response to infliximab (Olsen T et al., 2010). Homozygous 
carriers of IBD risk-increasing IL-23 receptor variants are more likely to respond to 
infliximab (Jurgens et al., 2010).  
4.3 Antiinflammatory cytokines 
4.3.1 Transforming growth factor-β 
Transforming growth factor-ǃ1 (TGF-ǃ1) is a potent regulatory cytokine, and has in the 
absence of IL-6, an antiinflammatory effect. Increased levels of TGF-ǃ1 are found both in CD 
and UC (Lawrance et al., 2001; Olsen T et al., 2011b), which are correlated with the severity of 
disease in CD but not in UC (Olsen T et al., 2011b). 
4.3.2 IL-10 
IL-10 has anti-inflammatory effects on proinflammatory cytokines (IL-1, IL-6, TNF-α) and its 
mucosal levels were found increased both in CD and UC (Akagi et al., 2000; Olsen et al., 
2007) (for review see(Kaser et al., 2010)) except for a single study(Nielsen et al., 1996). Of 
interest, mucosal levels of IL-10 and IL-4 in UC did not correlate with the treatment effects 
of infliximab (Olsen et al., 2009) and were not found reduced after infliximab treatment 
(Agnholt et al., 2003). 
4.3.3 IL-11 
IL-11 mediates anti-inflammatory effects by downregulation of LPS-induced NFkB 
activation preceding transcription of inflammatory genes. In the mucosal gene signature 
study of Arijs et al (Arijs et al., 2009) (39) IL-11 was one of several expressed genes 
separating responders from non-responders on infliximab treatment. 
4.4 Molecules of activation 
4.4.1 Adhesion molecules and chemokines 
4.4.1.1 The adhesion molecules play an important role in mediating intestinal injury by T 
cells in IBD  
The endothelium plays a key role in the pathogenesis of IBD acting as “gatekeeper” 
regulating the leukocyte trafficking through cell adhesion molecules and chemokine 
secretion. Integrins, selectins and immunoglobulins are receptors on leukocytes, 
endothelium, and platelets with their respective ligands which are up-regulated by 
proinflammatory cytokines through a NF-κB dependent mechanism.  Integrin α4β7 
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expressed on lymphocytes and its specific ligand mucosal vascular addressin on the 
endothelial cells play a pivotal role in the recruitment of leucocytes from blood to the 
inflamed tissue. An increased expressions of several adhesion molecules such as e-selectin, 
intracellular adhesion molecule-1 and 2 (ICAM-1, ICAM 2) and vascular cell adhesion 
molecule (VCAM) have been found in IBD (for review see (Danese et al., 2005). Although the 
leukocyte recruitment by adhesion molecules plays a role in the initiation and progression 
of the disease, there is little documentation of their roles as biomarkers. The gene expression 
of ICAM-1 is elevated in UC but was not correlated with response to steroids (Raddatz et al., 
2004). In the same study low expression of the glucocorticoid receptor was correlated to 
non-response. Of interest, in the study of Nicolaus et al (Nikolaus et al., 2000) relapsers after 
induction therapy with infliximab in CD were characterized by an increase in the TNF-α 
secretion capacity and increased mucosal nuclear NF-κB p65 before recurrence of clinical 
symptoms. Chemokines and their corresponding receptors are responsible for the 
chemotaxis and the adhesion and directional homing of immune and inflammatory cells 
from blood to tissue. The exact immunopathogenic role of chemokines in IBD is not clearly 
understood. However, increased tissue expressions of these molecules in IBD reflect 
increased trafficking and lymphocytes recirculation and neo-lympho organogenesis in the 
intestinal mucosa mediating not only inflammatory process but also repair mechanisms (for 
review see (Zimmerman et al., 2008)).    
4.4.2 Markers of tissue injury 
Among the effector mechanisms activated during intestinal inflammation are the key 
mediators such as inducible nitric oxide synthase (INOS), the apoptosis-related Granzyme B 
(GZNB), and the system of extracellular matrix degradation mediated by metalloproteinases 
(MMP). The pathophysiological role of nitric oxide in IBD is to some extent controversial. 
Increased INOS activity has been shown especially in UC (Palatka et al., 2005) and predicted 
the progression in IBD (Menchen et al., 2004). Some of MMPs are proinflammatory and 
found dysregulated in IBD (MMP-1,-3,-9, -12, -13) (Ravi et al., 2007; von et al., 2000). The 
tissue inhibitor of MMPs (TIMP) has reported to correlate both, positively (macrophage 
TIMP-1) and negatively (epithelial TIMP-3) to the disease activity in CD, whereas MMPs 
and TIMPs were decreased after treatment of the disease (Makitalo et al., 2009). In one report 
infliximab reduced a genotype-associated matrix protective phenotype (Meijer et al., 2007).  
4.4.3 Genomics 
There is increasing number of IBD suspectibility loci/genes discovered. There is beyond the 
goal of this review of mucosal biomarkers to describe the genomics in IBD.  In short, the 
most powerful tool is the use of genome-wide association (GWA) scanning in genotyping. In 
2011, 71 and 47 suspectibility loci/genes have been discovered in CD and UD, respectively, 
including 28 in common comprising the total number of 99 loci involved. (Anderson et al., 
2011;Franke et al., 2010). This genetic polymorphism linked to the innate immunity, 
autophagy, defective barrier, IL-10 signalling and adaptive immunity. Of these suspectibility 
loci/genes some have also been candidate biomarkers.  Polymorphisms in apoptopic genes 
(Fas/LFas system and caspace-9 influence the response of infliximab in luminal and fistulising 
Crohn’s disease (Hlavaty et al., 2005). Using GWA technology a loci (21q22,212IBRWDI) 
remained significant  for responsiveness to anti TNF therapy in children (Franke et al., 2010). 
There are now several IBD studies worldwide using the GWA technology and functional 
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genomics. Hopefully, these genome analyses together with gene expression analyses can 
define new subtypes of clinical outcomes and response to various treatment regimes. 
4.4.4 Proteomics 
Proteomics identifies biomarkers at protein expression levels in tissue and opens for protein 
dynamic mapping of proteins in the inflammatory pathways and their metabolic end 
products. So far, no mucosal proteomics have been reported in IBD, whereas 4 biomarkers 
of acute phase inflammation have been found in serum from patients with IBD (Meuwis et 
al., 2008a) and the chemokine platelet aggregation factor 4 (PF4) in serum predicted the 
response to infliximab in CD (Meuwis et al., 2008b). Of special interest is the fingerprinting 
of oxidative stress in inflammation and modification of proteins and thereby new potential 
biomarkers. So far, we are waiting for prospective studies relating fingerprints in mucosa to 
severity of disease and predictors to treatment. 
4.4.5 Metabolomics 
Metalobomics is the study of chemical fingerprints of all metabolites in the biological 
organism and represents the end product of the gene transcriptions. By the use of nuclear 
magnetic resonance (NMR) spectroscopy and mass spectrometry (MS) simultaneously 
assessment of numerous of metabolites corresponding to the “metabolome” and its end-
points of metabolic products may be done. Thus, in UC different metabolic profiles have 
been observed in biopsies when compared to controls (Bjerrum et al., 2010). In CD, pathways 
with differentiating metabolites included those involved in the metabolism and or synthesis 
of amino acids, fatty acids, bile acids and arachidonic acid, several metabolites were 
positively or negatively correlated to the disease phenotype (Jansson et al., 2009). Finally, in 
fecal extracts low levels of butyrate and acetate and amino acids have been observed in IBD 
compared to the controls (Marchesi et al., 2007). This opens for new insight of the 
etiopathogenesis of the disease. However, so far we do not know how this technology can 
contribute to the discovery of new biomarkers.  
5. Concluding remarks 
There are so far very few documentations of mucosal (by biopsy) or body fluid (non-
invasive) biomarkers predicting long-term clinical outcome or response to treatment. The 
most promising candidate predictors are TNF-ǂ but no validation data exists. In general, 
there is a need for prospective studies with a broad fingerprinting assay from mucosa as 
well as from body fluids. From a theoretical point of view, mediators of inflammation and 
their metabolites correlating with severity of disease are the candidates of greatest interest. 
After documentation of a candidate biomarker, there is a need of both a validation and 
adjustments of practical use for the clinicians. Therefore, biomarkers of IBD are still in the 
start of defining candidates of interest. 
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